Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 29th Jul 2014 09:37

Abderdeen Asset Management: Berenberg cuts target price from 530p to 510p and maintains a buy recommendation.African Barrick Gold: Numis takes target price from 260p to 330p upgrading from hold to buy.Anglo American: Deutsche Bank increases target price from 1590p to 1650p and reiterates a hold recommendation. Investec raises target price from 1630p to 1760p and keeps a hold recommendation.APR Energy: Investec places its target price (prev.: 880p) under review, while keeping a hold recommendation.Barclays: Numis upgrades from add to buy with a target price of 280p.Brammer: Investec cuts target price from 450p to 435p, while upgrading from hold to buy.BSkyB: Westhouse Securities upgrades from neutral to add with a target price of 985p.BTG: Jefferies ups target price from 525p to 760p upgrading from hold to buy.Compass Group: Deutsche Bank raises target price from 1025p to 1105p and retains a buy recommendation.Daily Mail & General Trust: Credit Suisse reinstates with a target price of 1040p and an outperform rating.Drax Group: Goldman Sachs cuts target price from 1098p to 1052p retaining a strong buy recommendation.Gem Diamonds: FinnCap ups target price from 211p to 261p and maintains a buy recommendation. Westhouse Securities ups target price from 220p to 235p and reiterates its buy recommendation.GKN: Numis upgrades from add to buy with a target price of 435p.GlaxoSmithKline: Berenberg reduces target price from 1740p to 1520p, while leaving its hold recommendation unchanged.Hiscox: Deutsche Bank cuts target price from 658p to 646p staying with its sell recommendation. Canaccord Genuity shifts target price from 705p to 710p and reiterates a hold recommendation.HSBC Holdings: Deutsche Bank reduces target price from 640p to 593p and reiterates a hold recommendation.Hutchison China Meditech: Panmure Gordon raises target price from 950p to 1200p keeping a buy recommendation.Informa: Canaccord Genuity cuts target price from 535p to 515p staying with its hold recommendation.Jardine Lloyd Thompson: Numis cuts target price from 1190p to 1120p downgrading from add to hold.Ladbrokers: Deutsche Bank lowers target price from 177p to 165p and keeps a buy recommendation.Lancashire Holdings: Berenberg reduces target price from 720p to 666p keeping a hold recommendation.Pace: Numis reduces target price from 420p to 360p and reiterates a hold recommendation.Petra Diamonds: Beaufort upgrades to buy. Numis ups target price from 220p to 240p, while downgrading from buy to add.Provident Financial: Espirito Santo raises target price from 1808p to 2012p and retains a neutral rating.Reckitt Benckiser: Credit Suisse raises target price from 5200p to 5500p and maintains an outperform rating. Numis downgrades from add to hold with a target price of 5600p.Sinclair IS Pharma: Jefferies lowers target price from 50p to 45p staying with its buy recommendation.Spectris: Goldman Sachs reduces target price from 3050p to 2770p and keeps its strong buy recommendation. Credit Suisse reduces target price from 2560p to 2370p and leaves its outperform rating unaltered. Canaccord Genuity reduces target price from 2700p to 2400p and downgrades from buy to hold.Sweett Group: N+1 Singer cuts target price from 61p to 45p retaining a buy recommendation.Tesco: Shore Capital upgrades from sell to hold.Treatt: Investec moves target price from 150p to 160p reiterating a hold recommendation.Tullett Prebon: Numis places both its target price (prev.: 299p) and its reduce rating under review. Liberum Capital places its target price (prev.: 240p) under review with a sell recommendation. Canaccord Genuity places both its target price and recommendation under review.William Hill: Deutsche Bank cuts target price from 435p to 415p leaving its buy recommendation unchanged.Zoopla Property: Credit Suisse initiates with a target price of 290p and an outperform rating.7Digital: Investec initiates with a target price of 37p and a buy recommendation.
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.